PROTHENA CORP PUBLIC LTD COPRTAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Prothena Corporation plc is a late-stage clinical biotechnology firm focused on developing and commercializing innovative antibody therapies for neurodegenerative disorders, rare diseases and immune-related conditions. Its core pipeline targets unmet medical needs including amyloidosis, Parkinson's and Alzheimer's, serving key markets across North America, Europe and the Asia-Pacific.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| FMR LLC | 15.00% | 8.0M | — | 2024-02-09 |
| Wellington Management Group LLP | 7.77% | 4.2M | ▼ -3.01pp | 2024-11-08 |
| William P. Scully | 7.50% | 4.0M | ▲ +0.97pp | 2024-11-13 |
| T. ROWE PRICE ASSOCIATES, INC. | 7.10% | 3.8M | ▼ -0.80pp | 2024-11-14 |
| BlackRock, Inc. | 7.00% | 3.8M | — | 2024-02-02 |
| Todd W. Fennell | 5.89% | 3.2M | flat | 2024-11-13 |
| STATE STREET CORPORATION | 3.10% | 1.7M | ▼ -2.04pp | 2024-10-18 |
| NOS. OF ABOVE PERSONS | 0.00% | 72.8M | — | 2024-02-13 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.